SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL System
SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed to be implanted during routine cataract surgery to deliver long-term IOP reduction in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
The BIM-IOL System delivers sustained release of bimatoprost, a prostaglandin analog approved to reduce elevated IOP, over multiple years. The new data highlight the system’s potential to transform glaucoma management by addressing one of the field’s greatest challenges—patient adherence to daily topical medications.
At 24 months, patients in the trial experienced a 42% reduction in mean IOP, decreasing from 25.1 ± 2.5 mmHg at baseline (post-washout) to 14.5 ± 3.0 mmHg (P<0.0001). This reduction was consistent across all three dosage groups tested. Notably, 100% of patients remained off all topical IOP-lowering medications, and all achieved best corrected distance visual acuity (BCDVA) of 20/30 or better.
The system was well tolerated, with no serious adverse events reported. All observed events were related to the cataract procedure rather than the device itself.
“Adherence with daily topical IOP-lowering medications is one of the most consistent challenges for patients in the management of glaucoma and ocular hypertension,” said Malik Kahook, MD, Co-founder of SpyGlass Pharma. “The findings at 24 months demonstrated that patients can achieve meaningful and durable reduction in IOP without the burden of daily drops. We are pleased to share these interim results and continue our objective of delivering a long-term, drop-free solution for patients in need.”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma, added: “The 24-month findings from our first-in-human trial add to our growing body of data supporting the long-term durability of the BIM-IOL System. With an implantation technique familiar to all cataract surgeons, including the two-thirds who do not routinely perform minimally invasive glaucoma surgery, we believe our system has the potential to become a widely implemented solution for reducing reliance on topical medication.”
About the Clinical Program
The ongoing single-center, prospective first-in-human trial is designed to evaluate the BIM-IOL System for safety and efficacy in reducing elevated IOP among OAG and OHT patients undergoing cataract surgery. SpyGlass Pharma has also completed enrollment in a phase 1/2 study to investigate the system’s safety and efficacy in a broader patient population.
The company plans to initiate two registrational phase 3 clinical trials by the end of the year, with the goal of advancing toward FDA approval and eventual commercialization of the BIM-IOL System.